pentoxifylline
pentoxifylline.JPG

CLINICAL USE

Peripheral vascular disease Venous leg ulcers (unlicensed indication)

DOSE IN NORMAL RENAL FUNCTION

400 mg 2 to 3 times daily

PHARMACOKINETICS

  • Molecular weight                           :278.3
  • %Protein binding                           :0
  • %Excreted unchanged in urine     : 0 (95% as active metabolites)
  • Volume of distribution (L/kg)       :2.4–4.2
  • half-life – normal/ESRD (hrs)      :0.4–1/Unchanged (see ‘Other Information’)

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–50 Dose as in normal renal function10–30 Reduce dose by 30–50% depending on individual tolerance (400 mg once or twice daily)
  • <10           : Reduce dose by 30–50% depending on individual tolerance (400 mg once or twice daily)

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. 400 mg daily, slowly increasing if necessary
  • HD                     :Not dialysed. 400 mg daily, slowly increasing if necessary
  • HDF/high flux   :Unknown dialysability. 400 mg daily, slowly increasing if necessary
  • CAV/VVHD      :Not dialysed. Dose as in GFR=10–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Analgesics: possibly increased risk of bleeding when administered in combination with NSAIDs; increased risk of bleeding with ketorolac – avoid concomitant use

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    May enhance hypoglycaemia Avoid in porphyria Active metabolites are renally excreted and have an extended half-life in renal impairment



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs